Tricyclic compounds as anticancer agents

US9751879B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Derek J. Norris · Pennington, US
• George V. DeLucca · Wilmington, US
• Ashvinikumar V. Gavai · Princeton Junction, US
• Claude A. Quesnelle · Skillman, US
• Patrice Gill · Fort Lee, US
• Daniel O'Malley · New Hope, US
• Wayne Vaccaro · Yardley, US
• Francis Y. Lee · Yardley, US
• Mikkel V. Debenedetto · Shrewsbury, US
• Andrew P. Degnan · New Haven, US
• Haiquan Fang · Madison, US
• Matthew D. Hill · Wallingford, US
• Hong Huang · Longbeilingcun, CN
• William D. Schmitz · Cheshire, US
• John E. Starrett, Jr. · Middletown, US
• Wen-Ching Han · Newtown, US
• John S. Tokarski · Princeton, US
• Sunil Kumar Mandal · Bengaluru, IN

Key dates

• Filing date: Jul 26, 2016
• Grant date: Sep 5, 2017
• Expiry date: Jul 26, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.